Unit 1 Pharmacology and Cell Pathophysiology Vocabulary

Fundamental Cellular Structures and Energy Production

  • Cell as the Basic Unit of Life: Foundational to both pathophysiology and pharmacology.

  • Organelle Structure and Function:

    • Nucleus: Serves as the control center and contains genetic material (DNA).

    • Mitochondria: Known as the powerhouse of the cell; primary site for the production of adenosine triphosphate (ATP\text{ATP}).

    • Ribosomes: Responsible for protein synthesis.

    • Endoplasmic Reticulum (ER): Facilities the transport of proteins and lipids.

    • Golgi Apparatus: Packages proteins for delivery or secretion.

    • Lysosomes and Peroxisomes: Functions in waste disposal, detoxification, and enzymatic digestion.

    • Plasma Membrane: Acts as a semi-permeable barrier and regulator of transport between the intracellular and extracellular environments.

  • Core Cellular Processes:

    • Energy production.

    • Protein synthesis.

    • Cellular communication.

    • Reproduction through mechanisms of mitosis and meiosis.

  • Aerobic Energy Production: Consists of the sequence: Glycolysis \rightarrow Kreb’s Cycle \rightarrow Electron Transport Chain (ETC). This process yields approximately 3236ATP32 - 36\,\text{ATP}.

Cellular Adaptive Responses and Pathognomonic Identifiers

  • Homeostasis and Adaptation: Cells undergo changes to maintain stability.

    • Adaptive (Functional): Compensatory and reversible changes.

    • Maladaptive (Dysfunctional): Changes that may lead to disease states.

  • Types of Adaptations:

    • Atrophy: A decrease in cell size (physiologic or pathologic) occurring via protein degradation and autophagy. Example: Disuse atrophy seen in a casted limb or the aging brain.

    • Hypertrophy: An increase in cell size due to stimulus or workload.

      • Physiologic: Weight training (skeletal muscle).

      • Pathologic: Left Ventricular Hypertrophy (LVH) due to hypertension, which is maladaptive and increases the risk of heart failure.

    • Hyperplasia: An increase in the number of cells via mitotic activity. Example: Endometrial hyperplasia or Keloid formation.

    • Metaplasia: Conversion from one adult cell type to another due to chronic irritation. Example: Barrett’s esophagus (squamous cells change to columnar cells). It is reversible but carries a risk of progression to dysplasia.

    • Dysplasia: Deranged, disordered growth characterized by atypical nuclei and mitotic figures; often considered a precancerous condition. Example: Cervical dysplasia related to HPV.

    • Neoplasia: Uncontrolled, autonomous, and new cell growth. It is irreversible and a hallmark of cancer.

      • Benign Neoplasia: New growth that is not harmful (e.g., a nevus/mole).

      • Malignant Neoplasia: Cancerous growth that is destructive and capable of metastasis.

  • Diagnostic Terms:

    • Etiology: The cause or origin of a disease (e.g., sun exposure for skin cancer).

    • Biopsy: The extraction of tissue for diagnostic examination.

    • Histology: The microscopic study of tissues.

    • Pathognomonic Changes: Unique, identifying features specific to a particular disease. Example: The mucosal crater of a peptic ulcer visible on endoscopy.

Mechanisms and Etiologies of Cellular Injury

  • Sodium/Potassium (Na+/K+Na^+/K^+) Pump Dysfunction: Fails when ATPATP is low. Leads to the accumulation of intracellular Na+Na^+, resulting in water influx and cellular swelling. Muscles and nerves lose polarity, causing lethargy and fatigue.

  • Calcium (Ca++Ca^{++}) Pump Dysfunction: Maintenance of low intracellular Ca++Ca^{++} requires ATPATP. Pump failure causes Ca++Ca^{++} accumulation, which activates enzymes that damage membranes and DNA. This can lead to pathological calcifications as seen in arteriosclerosis, malignancy, or stenotic valve disease.

  • Loss of Membrane Integrity: Allows entry of water and toxins; exposes the nucleus and organelles. Leads to energy failure (mitochondrial damage), lysis (lysosomal leakage), and inability to regenerate (nuclear damage).

  • Intracellular Accumulations: Can be reversible or toxic.

    • Fat: Examples include alcoholic liver disease.

    • Cholesterol: Examples include xanthomas.

    • Environmental Agents: Such as coal dust.

    • Bilirubin: Causes jaundice.

  • Genetic Damage: DNA mutations lead to abnormal RNA/proteins, potentially resulting in tumor formation if apoptosis or differentiation is bypassed.

  • Major Causes of Injury:

    • Hypoxia: The most common cause; inadequate oxygen supply leads to anaerobic metabolism and lactic acid buildup.

    • Free Radicals: Toxic by-products of mitochondrial oxidative phosphorylation (respiratory burst). Neutralized by antioxidants (Vitamins A, C, E) and superoxide dismutases. Oxidative stress occurs when radicals exceed neutralizers. Example: Ischemia-reperfusion injury after MI or stroke.

    • Physical Agents: Trauma, burns, frostbite, and radiation.

    • Chemical Injury:

      • Endogenous: Hyperglycemia, hypernatremia.

      • Exogenous: Carbon Monoxide (CO) poisoning, alcohol (leads to fatty liver changes), and nephrotoxic or hepatotoxic drugs.

    • Infectious Agents: Bacteria (H.pyloriH.\,pylori) and viruses (HPV, HIV).

    • Immunologic Reactions: Allergies and autoimmune disorders like Rheumatoid Arthritis (RA).

    • Nutritional Imbalances:

      • Kwashiorkor: Protein starvation leading to ascites.

      • Marasmus: Calorie and protein starvation leading to cachexia.

Clinical Consequences of Ischemia and Endothelial Dysfunction

  • Ischemia Tolerance by Tissue Type:

    • Brain: 36minutes3 - 6\,\text{minutes} (least tolerant due to high metabolic demand).

    • Heart (Myocardium): 2030minutes20 - 30\,\text{minutes}.

    • Kidney: 3060minutes30 - 60\,\text{minutes}.

    • Skeletal Muscle: 23hours2 - 3\,\text{hours}.

    • Skin: Several hours.

  • Ischemia Outcomes: Ischemic stroke (brain), Myocardial Infarction (heart), Acute tubular necrosis (kidney), Necrosis/perforation (bowel), and Gangrene (limbs).

  • Endothelial Function: The endothelium lines all blood vessels and regulates vascular tone.

    • Secretions: Vascular Endothelial Growth Factor (VEGF) for angiogenesis, Nitric Oxide (NO) for vasodilation, and Endothelin for vasoconstriction.

    • Endothelial Injury: The initial trigger for atherosclerosis.

    • Causes of Endothelial Injury: Hypertension (shear force), Hyperglycemia (glycation and AGEs), Free radicals (smoking), Angiotensin II (vasoconstriction), and LDL (foam cell/plaque formation).

Programmed Cell Death and Pathological Necrosis

  • Apoptosis: Programmed, essential cell death for removing unwanted cells and maintaining homeostasis.

    • Physiologic Examples: Embryogenesis (webbing removal), immune regulation (T-cell elimination), menstrual shedding, and skin/GI turnover.

    • Dysregulation:

      • Excessive: Leads to tissue loss (e.g., Spinal muscular atrophy, Hashimoto’s thyroiditis).

      • Inhibited: Leads to tumor growth (e.g., Prostate cancer, BPH).

  • Necrosis: Uncontrolled cell death due to severe injury, resulting in cell lysis and inflammation.

    • Types of Necrosis:

      • Coagulative: Protein denaturation; architecture is preserved (e.g., MI).

      • Liquefactive: Enzymatic digestion of tissue (e.g., Brain infarction, abscess).

      • Caseous: "Cheesy" appearance; combination of coagulative and liquefactive (e.g., Tuberculosis).

      • Fat Necrosis: Enzymatic destruction of fat (e.g., Acute pancreatitis).

  • Gangrene: Large area of necrotic tissue.

    • Dry: Ischemic, tissue shrinks and turns black.

    • Wet: Bacterial infection, swelling, foul odor.

    • Gas: Caused by ClostridiumperfringensClostridium\,perfringens; produces gas and spreads rapidly.

Basics of Pharmacology: Naming and Classification

  • Drug Classification:

    • Pharmacologic Class: Based on the mechanism of action (e.g., ACE inhibitors).

    • Therapeutic Class: Based on the clinical use or condition treated (e.g., antihypertensives).

    • Naming Conventions: Classes often share suffixes (e.g., "-pril" for ACEIs).

  • Nomenclature:

    • Generic Name: The official, chemical name; one per drug (e.g., lisinopril, ibuprofen).

    • Brand (Trade) Name: Marketed/trademarked name chosen by the manufacturer; can be multiple (e.g., Advil, Motrin).

    • Bioequivalence: The FDA requires generic drugs to have the same active ingredient, strength, and route as the brand drug and provide the same clinical benefit.

  • Medication Categories:

    • Prescription (Rx): Require provider oversight and authorization.

    • Nonprescription (OTC): Safe for self-administration for minor ailments.

    • Controlled Substances: Scheduled IVI - V based on abuse potential (Schedule I = highest risk, e.g., Heroin; Schedule V = lower risk, e.g., acetaminophen with codeine).

  • Prescription Components: Must include Patient name, date, drug name, dose, route, frequency, duration/quantity, indication for PRN meds, provider signature, and DEA number if applicable.

Pharmacokinetics: The Life Cycle of a Drug (ADME)

  • Pharmacokinetics: The movement and modification of a medication inside the body.

  • Absorption: Movement from the site of administration into the bloodstream. Influenced by route, formulation (Extended Release [XR], Enteric Coated [EC]), blood flow, and pH.

    • First-Pass Effect: Reduced bioavailability of oral drugs because they are metabolized by the liver before reaching systemic circulation.

  • Distribution: Movement through the bloodstream to tissues. Influenced by blood flow, protein binding (primarily albumin), and barriers like the Blood-Brain Barrier. High-perfusion organs like the heart, liver, and kidneys receive drugs first.

  • Metabolism (Biotransformation): Occurs mostly in the liver via CYP450 enzymes.

    • Phase I (Oxidation): Introduces/exposes functional groups (OH,NH2,SH-OH, -NH_2, -SH). Can activate a drug (e.g., Codeine \rightarrow Morphine via CYP2D6).

    • Phase II (Conjugation): Attaches a water-soluble molecule (glucuronic acid, sulfate, glutathione). This increases water solubility to facilitate excretion. (e.g., Morphine \rightarrow Morphine-6-glucuronide).

  • Excretion: Removal via kidneys, bile, lungs, or sweat. Also occurs through mammary and seminal glands.

Pharmacodynamics: Mechanisms of Action and Drug Interactions

  • Pharmacodynamics: Description of how a drug acts on the body (Mechanism of Action [MOA]).

  • Receptor Interaction:

    • Agonist: Activates receptors for a full response (e.g., morphine).

    • Antagonist: Blocks receptors to inhibit a response (e.g., naloxone).

    • Partial Agonist: Activates with a reduced response (e.g., buprenorphine).

  • Drug-Drug Interactions:

    • Additive Effect (1+1=21 + 1 = 2): Total effect is the sum of parts (e.g., Acetaminophen + Ibuprofen).

    • Synergistic Effect (1 + 1 > 2): Combined effect is greater than the sum (e.g., Alcohol + Benzodiazepines; Trimethoprim + Sulfamethoxazole).

    • Antagonistic Interaction: Drugs neutralize each other (e.g., Albuterol [Beta-agonist] + Propranolol [Beta-blocker]).

  • Adverse Drug Reactions (ADRs):

    • Beta-blockers: Can cause bradycardia by antagonizing cardiac beta cells.

    • ACE Inhibitors: Can cause a dry cough by blocking the conversion of Angiotensin I to II, leading to Bradykinin secretion in the lungs.

    • Organ Toxicity: Liver (statins, acetaminophen); Kidneys (NSAIDs, aminoglycosides).

Principles of Safe Medication Administration and Nursing Practice

  • Therapeutic Index (TI): The range between effective and toxic doses.

    • Wide TI: Safer (e.g., ibuprofen).

    • Narrow TI: Requires monitoring of peak and trough levels (e.g., warfarin, lithium).

  • Monitoring Parameters:

    • Onset: When effect begins.

    • Peak: Maximum effect.

    • Duration: How long effect lasts.

    • Half-life: Determines dosing frequency.

  • Factors Influencing Response:

    • Age: Neonates have immature organs; elderly have decreased function.

    • CYP450 System: Inducers (e.g., rifampin) decrease drug levels; Inhibitors (e.g., grapefruit juice) increase drug levels.

    • Pharmacogenomics: African American individuals may have lower baseline renin activity, making ACE inhibitors less effective. CYP2D6 poor metabolizers might find codeine ineffective.

  • Pregnancy Categories: Range from AA to XX, where Category XX is contraindicated due to teratogenicity.

Routes of Administration: Clinical Considerations and Patient Education

  • Oral (PO)/Enteral: Convenient but has slower onset and first-pass effect. Nursing: Ensure High Fowlers, check swallowing/tube placement. Education: No crushing XR/EC; follow food instructions.

  • Topical/Transdermal: Localized; avoids first-pass. Nursing: Rotate sites, wear gloves, apply to intact skin. Education: Do not cut patches.

  • Inhalation: Rapid absorption, targeted to lungs. Nursing: Assess breath sounds, rinse mouth post-use. Education: Use of spacers; rinse to prevent thrush.

  • Parenteral (IV, IM, SubQ, ID): Rapid onset (especially IV), bypasses GI. Nursing: Sterile technique, site rotation (e.g., for insulin).

  • Rectal/Vaginal: Useful when PO is contraindicated. Nursing: Sim’s position for rectal; use lubrication. Education: Lie down for 510minutes5 - 10\,\text{minutes} after.

Questions & Discussion

  • Question: A nurse notices a patient is taking both Motrin and ibuprofen. What is the appropriate action?

    • Answer: Notify the provider; the patient is duplicating therapy (both are ibuprofen).

  • Question: What is the primary purpose of an adaptive cellular change in response to injury?

    • Answer: To enable cells to survive and maintain function under persistent stress.

  • Question: A pathology report indicates deranged cellular growth, varying size/shape, and describes it as precancerous. What is this?

    • Answer: Dysplasia.

  • Question: Alcohol abuse leading to fatty changes in the liver is what kind of injury?

    • Answer: Chemical injury.

  • Question: After 25 minutes of coronary artery occlusion, what is most likely?

    • Answer: Irreversible injury to cardiac muscle has begun (tolerance is 2030minutes20 - 30\,\text{minutes}).

  • Question: Why does a diabetic patient develop vascular complications?

    • Answer: Endothelial injury via glycation and endothelin secretion.